-
Eli Lilly PD-1 was exposed to performance shrinkage, Junshi laid off tens of billions of employees, "Red Sea" fierce competition
Time of Update: 2021-07-14
According to the news, for the national market, Eli Lilly and Cinda are currently jointly promoting PD-1, but sales this year seem to be sluggish.
-
10 domestic 1 class of new drugs "on the market take off"! Zhengda sunny, Hengrui, Howson lit up, the three PD-1 total broke 10 billion?
Time of Update: 2021-03-24
Its medical insurance effect is fully reflected in 2019, when the terminal sales of Anlotinib in China's public medical institutions exceeded 2 billion yuan, and it became a veritable large variety in the second year of its listing.
-
The world's first off-skin injection of PD-L1 antibodies! Corning Jerry KN035 (Nwolly single anti
Time of Update: 2021-01-26
January 19, 2021 // -- Corning Jerry Biopharmaceuticals ("Corning Jerry") recently announced that its recombinant humanized PD-L1 mono-domain antibody Nvolly monoantigen injection (research and develo
-
The first off-skin injection PD-L1! Corning Jerry/ Idea Dean Worley single anti-trump priority...
Time of Update: 2021-01-21
open label Phase II study evaluated the safety and anti-tumor activity of KN035 in patients with advanced MSI-H/dMMR cancer.
-
4,400 clinical trials are under study worldwide! The latest trend of PD-1/PD-L1 at the top of the wind is worth turning off
Time of Update: 2021-01-20
Figure 2.2: A comparison of monotherapy and combination therapy clinical trials shows that over the past seven years, the average number of planned patients in each single-drug clinical trial fell by as much as 500 percent from 854 in 2014 to 131 in 2020.
-
The world's first off-the-skin injection of PD-L1 antibody Nwolly monoantigen injection was submitted to China for the new drug market application
Time of Update: 2020-11-29
(3D Pharmaceuticals Inc.) has reached a strategic partnership to restructure the humanized PD-L1 mono-domain antibody Nvolly monoantigen injection (research and development code: KN035) of the new drug market application (NDA), has been officially Submitted to the National Drug Administration (NMPA), the application for adaptation is for the treatment of advanced colorectal cancer (MSI-H) advanced colorectal cancer, stomach cancer and other mismatch repair functional defects (dMMR) advanced solid tumors that have failed in previous standard treatments.
-
The first off-the-skin injection PD-L1 was declared public in China for priority review.
Time of Update: 2020-10-03
agreement provides that CorningEry is the sole manufacturer of KN035, responsible for the production and supply of KN03Chinese mainland5; Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Met Medical".